ES2582091T3 - Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas - Google Patents

Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas Download PDF

Info

Publication number
ES2582091T3
ES2582091T3 ES13164628.3T ES13164628T ES2582091T3 ES 2582091 T3 ES2582091 T3 ES 2582091T3 ES 13164628 T ES13164628 T ES 13164628T ES 2582091 T3 ES2582091 T3 ES 2582091T3
Authority
ES
Spain
Prior art keywords
meganuclease
binding affinity
dna binding
sequence
sequence specificity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13164628.3T
Other languages
English (en)
Inventor
Homme W. Hellinga
James Jefferson Smith
Derek Jantz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PREC BIOSCIENCES
Precision Biosciences Inc
Original Assignee
PREC BIOSCIENCES
Precision Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37963286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2582091(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PREC BIOSCIENCES, Precision Biosciences Inc filed Critical PREC BIOSCIENCES
Application granted granted Critical
Publication of ES2582091T3 publication Critical patent/ES2582091T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/905—Stable introduction of foreign DNA into chromosome using homologous recombination in yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Una meganucleasa recombinante que comprende: un polipéptido que tiene una similitud de al menos el 85 % con los restos 2-153 de la meganucleasa I-CreI de SEQ ID NO: 1; en la que la afinidad de unión a ADN se ha aumentado mediante al menos una modificación de un resto que es parte de la superficie de contacto de la estructura de la meganucleasa I-CreI de SEQ ID NO: 1, correspondiendo dicha modificación a una sustitución seleccionada entre el grupo que consiste en: sustitución de E80 por H, N, Q, S, T, K o R.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
5
15
25
35
45
55
65
reconocen específicamente pero que constituyen el sitio de escisión real (que tiene un saliente de 4 pares de bases). Por lo tanto, las secuencias de reconocimiento combinadas de los dímeros de meganucleasa I-CreI, I-MsoI e I-CeuI normalmente abarcan 22 pares de bases, incluyendo dos semi-sitios de 9 pares de bases que flanquean un sitio de escisión de 4 pares de bases. Los pares de bases de cada semi-sitio se designan de -9 a -1, siendo la posición -9 la más distal del sitio de escisión y siendo la posición -1 adyacente a los 4 pares de bases centrales, que se designan N1-N4. La hebra de cada semi-sitio que se orienta de 5' a 3' en la dirección de -9 a -1 (es decir, hacia el sitio de escisión), se designa la hebra “sentido” y la hebra opuesta se designa la “hebra antisentido”, aunque ninguna de las hebras puede codificar proteína. Por lo tanto, la hebra “sentido” de un semi-sitio es la hebra antisentido del otro semi-sitio. Véase, por ejemplo, la Figura 1 (A). En el caso de la meganucleasa I-SceI, que es un monómero de meganucleasa di-LAGLIDADG, la secuencia de reconocimiento es una secuencia no palindrómica de aproximadamente 18 pb y no hay pares de bases centrales que no se reconozcan específicamente. Por convención, una de las dos hebras se denomina la hebra “sentido” y la otra la hebra “antisentido”, aunque ninguna de las hebras puede codificar proteína.
Como se usa en el presente documento, el término “especificidad” significa la capacidad de una meganucleasa para reconocer y escindir moléculas de ADN bicatenarias solamente en una secuencia particular de pares de bases denominada secuencia de reconocimiento, o solamente en un conjunto particular de secuencias de reconocimiento. El conjunto de secuencias de reconocimiento compartirá ciertas posiciones conservadas o motivos de secuencia, pero pueden degenerarse en una o más posiciones. Una meganucleasa altamente específica es capaz de escindir solamente una o muy pocas secuencias de reconocimiento. La especificidad puede determinarse en un ensayo de escisión como se describe en el Ejemplo 1. Como se usa en el presente documento, una meganucleasa tiene especificidad “alterada” si se une a y escinde una secuencia de reconocimiento que no está unida a y escindida por una meganucleasa de referencia (por ejemplo, de tipo silvestre) o si la tasa de escisión de una secuencia de reconocimiento aumenta o se reduce por una cantidad estadísticamente significativa (p < 0,05) en relación con una meganucleasa de referencia.
Como se usa en el presente documento, el término “degeneración” significa lo opuesto de “especificidad”. Una meganucleasa altamente degenerada es capaz de escindir un gran número de secuencias de reconocimiento divergentes. Una meganucleasa puede tener degeneración de secuencia en una posición sencilla dentro de un semisitio o en múltiples, incluso todas las, posiciones dentro de un semi-sitio. Dicha degeneración de secuencia puede resultar de (i) la incapacidad de cualquier aminoácido en el dominio de unión a ADN de una meganucleasa para realizar un contacto específico con cualquier base en una o más posiciones en la secuencia de reconocimiento, (ii) la capacidad de uno o más aminoácidos en el dominio de unión a ADN de una meganucleasa para realizar un contacto específico con más de una base en una o más posiciones en la secuencia de reconocimiento y/o (iii) suficiente afinidad de unión a ADN no específico para actividad. Una posición degenerada “completamente” puede ocuparse por cualquiera de las cuatro bases y puede designarse con una “N” en un semi-sitio. Una posición degenerada “parcialmente” puede ocuparse por dos o tres de las cuatro bases (por ejemplo, purina (Pu), pirimidina (Py) o no G).
Como se usa en el presente documento con respecto a meganucleasas, la expresión “afinidad de unión a ADN” o “afinidad de unión” significa la tendencia de una meganucleasa a asociarse de forma no covalente con una molécula de ADN de referencia (por ejemplo, una secuencia de reconocimiento o una secuencia arbitraria). La afinidad de unión se mide por una constante de disociación, KD (por ejemplo, la KD de I-CreI para la secuencia de reconocimiento WT es de aproximadamente 0,1 nM). Como se usa en el presente documento, una meganucleasa tiene afinidad de unión “alterada” si la KD de la meganucleasa recombinante para una secuencia de reconocimiento de referencia aumenta o se reduce en una cantidad estadísticamente significativa (p < 0,05) en relación con una meganucleasa de referencia.
Como se usa en el presente documento con respecto a monómeros de meganucleasa, la expresión “afinidad para formación de dímeros” significa la tendencia de un monómero de meganucleasa para asociarse de forma no covalente con un monómero de meganucleasa de referencia. La afinidad para formación de dímeros puede medirse con el mismo monómero (es decir, formación de homodímeros) o con un monómero diferente (es decir, formación de heterodímeros) tal como una meganucleasa de tipo silvestre de referencia. La afinidad de unión se mide por una constante de disociación, KD. Como se usa en el presente documento, una meganucleasa tiene afinidad “alterada” para formación de dímeros si la KD del monómero de meganucleasa recombinante para un monómero de meganucleasa de referencia aumenta o se reduce en una cantidad estadísticamente significativa (p < 0,05) en relación con un monómero de meganucleasa de referencia.
Como se usa en el presente documento, el término “palindrómico” se refiere a una secuencia de reconocimiento que consiste en repeticiones invertidas de semi-sitios idénticos. En este caso, sin embargo, la secuencia palindrómica no necesita ser palindrómica con respecto a los cuatro pares de bases centrales, que no entran en contacto con la enzima. En el caso de meganucleasas diméricas, las secuencias de ADN palindrómicas se reconocen por homodímeros en los que los dos monómeros realizan contactos con semi-sitios idénticos.
Como se usa en el presente documento, la expresión “pseudo-palindrómico” se refiere a una secuencia de reconocimiento que consiste en repeticiones invertidas de semi-sitios palindrómicos no idénticos o imperfectos. En este caso, la secuencia pseudo-palindrómica no solamente no necesita ser palindrómica con respecto a los cuatro pares de base centrales, sino que también puede desviarse de una secuencia palindrómica entre los dos semi-sitios.
8
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
con un ácido glutámico en la posición 26 (véase Figura 1(D)); una A en la hebra sentido podría realizar un enlace de hidrógeno con una glutamina en la posición 77 y una T en la hebra antisentido podría formar contactos hidrófobos con una alanina en la posición 26 (véase Figura 1 (E)). Si el contacto específico de base se proporciona por la posición 77, entonces el contacto de tipo silvestre, Q26, puede sustituirse (por ejemplo, con un resto de serina) para reducir o retirar
5 su influencia en la especificidad. Como alternativa, pueden combinarse mutaciones complementarias en las posiciones 26 y 77 para especificar un par de bases particular (por ejemplo, A26 especifica una T en la hebra antisentido y Q77 especifica una A en la hebra sentido (Figura 1 (E)). Todas estas sustituciones de restos predichas se han validado experimentalmente.
10 Por lo tanto, de acuerdo con la invención, se ha identificado una variedad sustancial de modificaciones de aminoácidos para el dominio de reconocimiento de ADN de la meganucleasa I-CreI que, individualmente o en combinación, dan como resultado meganucleasas recombinantes con especificidades alteradas en bases individuales dentro del semi-sitio de secuencia de reconocimiento de ADN, de modo que estas meganucleasas diseñadas racionalmente tienen semi-sitios diferentes de la enzima de tipo silvestre. Las modificaciones de aminoácidos de I-CreI y el cambio
15 resultante en la especificidad del semi-sitio de secuencia de reconocimiento se muestran en la Tabla 1:
TABLA 1
Base de hebra sentido favorecida
Posn.
A C G T A/T A/C A/G C/T G/T A/G/T A/C/G/T
-1
Y75 L75* C75* Y139* C46* A46* R70* H75* R75* H46* K46* R46* K70 E70* E75* E46* D46* Q70* C70 L70 Y75* Q75* H75* H139 Q46* H46* T46* G70 A70 S70 G46*
-2
Q70 T44* A44* V44* I44* L44* N44* E70 D70 K44* R44* H70 D44* E44* Q44* C44*
-3
Q68 C24* I24* E68 F68 K24* R24* R68 M68 C68 L68 F68 H68 Y68 K68
-4
A26* Q77 E77 K26* R77 E26* S77 Q26* S26*
-5
E42 R42 K28* C28* Q42 M66 K66
-6
Q40 C28* E40 R28* R40 C40 I40 V40 C79 I79 V79 Q28* A40 A79 A28* H28* S40 S28*
-7
N30* Q38 E38 K30* R30* K38 R38 E30* I38 L38 C38 H38 N38 Q30*
-8
F33 Y33 E33 D33 F33 H33 L33 V33 I33 F33 C33 R32* R33
16
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28

Claims (1)

  1. imagen1
    imagen2
ES13164628.3T 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas Active ES2582091T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72751205P 2005-10-18 2005-10-18
US727512P 2005-10-18

Publications (1)

Publication Number Publication Date
ES2582091T3 true ES2582091T3 (es) 2016-09-09

Family

ID=37963286

Family Applications (9)

Application Number Title Priority Date Filing Date
ES06826293T Active ES2425022T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES12162075.1T Active ES2440801T3 (es) 2005-10-18 2006-10-18 Meganucleasas racionalmente diseñadas con especificidad de secuencia y afinidad de unión a ADN alteradas
ES13164623.4T Active ES2539616T3 (es) 2005-10-18 2006-10-18 Meganucleasa diseñada racionalmente con afinidad de formación de dímeros alterada
ES13164628.3T Active ES2582091T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES10191904.1T Active ES2533370T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES10191888T Active ES2384440T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES13164585.5T Active ES2626025T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES13164564.0T Active ES2602184T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES17161899T Active ES2829549T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES06826293T Active ES2425022T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES12162075.1T Active ES2440801T3 (es) 2005-10-18 2006-10-18 Meganucleasas racionalmente diseñadas con especificidad de secuencia y afinidad de unión a ADN alteradas
ES13164623.4T Active ES2539616T3 (es) 2005-10-18 2006-10-18 Meganucleasa diseñada racionalmente con afinidad de formación de dímeros alterada

Family Applications After (5)

Application Number Title Priority Date Filing Date
ES10191904.1T Active ES2533370T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES10191888T Active ES2384440T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES13164585.5T Active ES2626025T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES13164564.0T Active ES2602184T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES17161899T Active ES2829549T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas

Country Status (9)

Country Link
US (20) US8021867B2 (es)
EP (13) EP3246403B1 (es)
JP (10) JP5937292B2 (es)
AT (1) ATE549401T1 (es)
AU (1) AU2006304668B2 (es)
CA (3) CA3055968A1 (es)
DK (9) DK2360244T3 (es)
ES (9) ES2425022T3 (es)
WO (1) WO2007047859A2 (es)

Families Citing this family (500)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078552A1 (en) † 2002-03-15 2006-04-13 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
WO2009095742A1 (en) * 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
JP2006518372A (ja) * 2003-01-28 2006-08-10 セレクティス 脊椎動物の体組織においてエクスビボかつイントトで相同的組換えを誘発するためのメガヌクレアーゼの使用およびその応用
EP2327773A1 (en) * 2005-03-15 2011-06-01 Cellectis I-crel meganuclease variants with modified specificity, method of preparation and uses thereof
US20090263900A1 (en) 2008-04-14 2009-10-22 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
WO2007060495A1 (en) * 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
AU2007267874B2 (en) * 2006-05-25 2012-03-15 Sangamo Therapeutics, Inc. Methods and compositions for gene inactivation
WO2008093152A1 (en) * 2007-02-01 2008-08-07 Cellectis Obligate heterodimer meganucleases and uses thereof
CA2678526A1 (en) * 2007-02-19 2008-08-28 Cellectis Laglidadg homing endonuclease variants having novel substrate specificity and use thereof
CN101688217B (zh) 2007-06-05 2013-04-03 拜尔作物科学公司 在真核生物中精确替换靶dna的方法和手段
KR20100023862A (ko) * 2007-06-22 2010-03-04 싸이도우스 엘엘씨. 트윈 80을 함유하지 않은 도세탁셀의 용해 제제
CA2691440A1 (en) * 2007-06-29 2009-01-08 Pioneer Hi-Bred International, Inc. Methods for altering the genome of a monocot plant cell
WO2009013559A1 (en) * 2007-07-23 2009-01-29 Cellectis Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof
WO2009019528A1 (en) * 2007-08-03 2009-02-12 Cellectis Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof
EP2188384B1 (en) * 2007-09-27 2015-07-15 Sangamo BioSciences, Inc. Rapid in vivo identification of biologically active nucleases
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
WO2009059195A2 (en) 2007-10-31 2009-05-07 Precision Biosciences Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
WO2009068937A1 (en) * 2007-11-28 2009-06-04 Cellectis I-msoi homing endonuclease variants having novel substrate specificity and use thereof
AU2008335324A1 (en) * 2007-12-07 2009-06-18 Precision Biosciences, Inc. Rationally-designed meganucleases with recognition sequences found in DNase hypersensitive regions of the human genome
AR070495A1 (es) 2008-02-29 2010-04-07 Monsanto Technology Llc Evento de maiz mon87460 y composiciones y metodos para detectarlo
WO2009114321A2 (en) * 2008-03-11 2009-09-17 Precision Biosciencs, Inc. Rationally-designed meganucleases for maize genome engineering
US20100071083A1 (en) * 2008-03-12 2010-03-18 Smith James J Temperature-dependent meganuclease activity
AU2009241351A1 (en) * 2008-04-28 2009-11-05 Precision Biosciences, Inc. Fusion molecules of rationally-designed DNA-binding proteins and effector domains
EP3495478A3 (en) * 2008-07-14 2019-07-24 Precision Biosciences, Inc. Recognition sequences for i-crei-derived meganucleases and uses thereof
EP2789691B1 (en) 2008-08-22 2018-08-08 Sangamo Therapeutics, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
KR101683928B1 (ko) * 2008-12-17 2016-12-07 다우 아그로사이언시즈 엘엘씨 Ｚｐ１５ 유전자 자리 내로의 표적화 통합
US8551945B2 (en) 2009-02-04 2013-10-08 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathies
US20110294217A1 (en) * 2009-02-12 2011-12-01 Fred Hutchinson Cancer Research Center Dna nicking enzyme from a homing endonuclease that stimulates site-specific gene conversion
EP2408921B1 (en) 2009-03-20 2017-04-19 Sangamo BioSciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
WO2010122367A2 (en) * 2009-04-21 2010-10-28 Cellectis Meganuclease variants cleaving the genomic insertion of a virus and uses thereof
US8772008B2 (en) * 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
EP2435560A2 (en) * 2009-05-26 2012-04-04 Cellectis Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof
WO2010136841A2 (en) * 2009-05-26 2010-12-02 Cellectis Meganuclease variants cleaving the genome of a non-genomically integrating virus and uses thereof
CA2765488C (en) * 2009-06-30 2018-01-02 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
US9234016B2 (en) 2009-07-28 2016-01-12 Sangamo Biosciences, Inc. Engineered zinc finger proteins for treating trinucleotide repeat disorders
DK2462230T3 (en) * 2009-08-03 2015-10-19 Recombinetics Inc METHODS AND COMPOSITIONS FOR TARGETED RE-MODIFICATION
JP5940977B2 (ja) 2009-08-11 2016-06-29 サンガモ バイオサイエンシーズ， インコーポレイテッド 標的改変によるホモ接合生物
BR122019025207B1 (pt) 2009-10-22 2022-10-04 Sangamo Biosciences, Inc. Proteína de dedo de zinco de ocorrência não natural e proteína de fusão
EP2319872A1 (en) 2009-11-04 2011-05-11 BASF Plant Science GmbH Amylopectin type starch with enhanced retrogradation stability
WO2011064736A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Optimized endonucleases and uses thereof
CN105384827A (zh) 2009-11-27 2016-03-09 巴斯夫植物科学有限公司 嵌合内切核酸酶及其用途
EP2504430A4 (en) 2009-11-27 2013-06-05 Basf Plant Science Co Gmbh CHIMERIC ENDONUCLEASES AND USES THEREOF
AU2010339481B2 (en) 2009-12-30 2016-02-04 Pioneer Hi-Bred International, Inc. Methods and compositions for targeted polynucleotide modification
US20110203012A1 (en) * 2010-01-21 2011-08-18 Dotson Stanton B Methods and compositions for use of directed recombination in plant breeding
EP2660318A1 (en) 2010-02-09 2013-11-06 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US20130227715A1 (en) * 2010-02-26 2013-08-29 Cellectis Use of endonucleases for inserting transgenes into safe harbor loci
CA2794037A1 (en) 2010-03-22 2011-09-29 Philip Morris Products S.A. Modifying enzyme activity in plants
WO2011139349A1 (en) 2010-05-03 2011-11-10 Sangamo Biosciences, Inc. Compositions for linking zinc finger modules
JP6208580B2 (ja) 2010-05-17 2017-10-04 サンガモ セラピューティクス， インコーポレイテッド 新規のｄｎａ結合タンパク質及びその使用
CA2801834A1 (en) * 2010-06-09 2011-12-15 Kathleen D'halluin Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering
CA2801836A1 (en) * 2010-06-09 2011-12-15 Bayer Cropscience Nv Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering
JP6050230B2 (ja) 2010-07-21 2016-12-21 サンガモ バイオサイエンシーズ， インコーポレイテッド Ｈｌａ遺伝子座の修飾のための方法及び組成物
EP2601297B1 (en) * 2010-08-02 2020-09-16 Cellectis Method for targeted genomic events in algae
EP2622090B1 (en) 2010-09-27 2019-06-19 Sangamo Therapeutics, Inc. Compositions for inhibiting viral entry into cells
CN103354715A (zh) 2011-01-14 2013-10-16 双刃基金会 具有针对柑橘溃疡病的抗性的柑橘树
BR112013024337A2 (pt) 2011-03-23 2017-09-26 Du Pont locus de traço transgênico complexo em uma planta, planta ou semente, método para produzir em uma planta um locus de traço transgênico complexo e construto de expressão
WO2012138901A1 (en) * 2011-04-05 2012-10-11 Cellectis Sa Method for enhancing rare-cutting endonuclease efficiency and uses thereof
BR112013028306B1 (pt) 2011-05-02 2020-04-07 Univ Nebraska plantas com características úteis e processos relacionados
EP2535416A1 (en) 2011-05-24 2012-12-19 BASF Plant Science Company GmbH Development of phytophthora resistant potato with increased yield
ES2773891T3 (es) 2011-06-01 2020-07-15 Prec Biosciences Inc Procedimientos para la producción de líneas celulares de mamífero modificadas con transgenes amplificados
CN103597082B (zh) 2011-06-06 2017-09-15 拜尔作物科学公司 用于在预选位点修饰植物基因组的方法和手段
US9758796B2 (en) 2011-06-10 2017-09-12 Basf Plant Science Company Gmbh Nuclease fusion protein and uses thereof
WO2013066423A2 (en) 2011-06-21 2013-05-10 Pioneer Hi-Bred International, Inc. Methods and compositions for producing male sterile plants
AR087167A1 (es) 2011-07-12 2014-02-26 Two Blades Foundation Genes de resistencia al tizon tardio
EP2737063B1 (en) 2011-07-25 2016-06-01 Sangamo BioSciences, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
AU2013204310C1 (en) * 2011-08-22 2015-12-10 BASF Agricultural Solutions Seed US LLC Methods and means to modify a plant genome
CN103890181A (zh) 2011-08-22 2014-06-25 拜尔作物科学公司 修饰植物基因组的方法和手段
CA2848417C (en) 2011-09-21 2023-05-02 Sangamo Biosciences, Inc. Methods and compositions for regulation of transgene expression
CA3099582A1 (en) 2011-10-27 2013-05-02 Sangamo Biosciences, Inc. Methods and compositions for modification of the hprt locus
EP2612918A1 (en) 2012-01-06 2013-07-10 BASF Plant Science Company GmbH In planta recombination
US9499831B2 (en) 2012-01-17 2016-11-22 Pioneer Hi-Bred International, Inc. Plant transcription factors, promoters and uses thereof
BR112014018294B1 (pt) 2012-01-26 2022-01-11 Norfolk Plant Sciences, Ltd Método para produzir uma planta, cassete de expressão, e, célula bacteriana
EP2820159B1 (en) 2012-02-29 2019-10-23 Sangamo Therapeutics, Inc. Methods and compositions for treating huntington's disease
US20150203864A1 (en) 2012-03-13 2015-07-23 University Of Guelph Myb55 promoter and use thereof
CN104302773A (zh) 2012-03-13 2015-01-21 圭尔夫大学 增加植物对热胁迫的耐受性及氨基酸含量的方法
BR112014026203A2 (pt) 2012-04-23 2017-07-18 Bayer Cropscience Nv engenharia do genoma direcionado nas plantas
HK1208052A1 (en) 2012-05-02 2016-02-19 陶氏益农公司 Targeted modification of malate dehydrogenase
CA2872096A1 (en) 2012-05-04 2013-11-07 E. I. Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
WO2013169802A1 (en) 2012-05-07 2013-11-14 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
CA2878037C (en) 2012-07-11 2021-08-31 Sangamo Biosciences, Inc. Methods and compositions for delivery of biologics
ES2613691T3 (es) 2012-07-11 2017-05-25 Sangamo Biosciences, Inc. Métodos y composiciones para el tratamiento de enfermedades por almacenamiento lisosomal
AU2013308770B2 (en) 2012-08-29 2019-01-17 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
EP3763810A3 (en) 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
DK2925864T3 (en) 2012-11-27 2019-02-11 Childrens Medical Ct Corp DIRECTIONAL TARGETING OF DISTANT BCL11A CONTROLS FOR FETAL HEMOGLOBIN REINUCTION
BR102013032200A2 (pt) 2012-12-13 2015-11-24 Dow Agrosciences Llc direcionamento preciso de um gene para um locus específico em milho
EP2958996B1 (en) * 2013-02-25 2019-10-16 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
DK2971039T3 (da) 2013-03-14 2020-04-06 Immusoft Corp Fremgangsmåder til in vitro-differentiering af hukommelses-b-celler og transduktion med vsv-g-pseudotypeomdannede virusvektorer
US20160053274A1 (en) 2013-04-02 2016-02-25 Bayer Cropscience Nv Targeted genome engineering in eukaryotes
WO2014165612A2 (en) 2013-04-05 2014-10-09 Dow Agrosciences Llc Methods and compositions for integration of an exogenous sequence within the genome of plants
WO2015006437A1 (en) 2013-07-10 2015-01-15 Majzoub Joseph A Mrap2 knockouts
CN120574876A (zh) 2013-08-22 2025-09-02 纳幕尔杜邦公司 使用向导rna/cas内切核酸酶系统的植物基因组修饰及其使用方法
EP3591045B1 (en) 2013-08-28 2024-07-17 Sangamo Therapeutics, Inc. Compositions for linking dna-binding domains and cleavage domains
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
US10767188B2 (en) 2013-09-25 2020-09-08 Nutech Ventures Methods and compositions for obtaining useful plant traits
KR20150037550A (ko) * 2013-09-30 2015-04-08 주식회사 엘지화학 국지적으로 편광 해소 영역을 갖는 편광판 및 그 제조 방법
WO2015057980A1 (en) 2013-10-17 2015-04-23 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US10117899B2 (en) 2013-10-17 2018-11-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
JP6633532B2 (ja) 2013-11-04 2020-01-22 ダウ アグロサイエンシィズ エルエルシー 最適なトウモロコシ遺伝子座
NZ735257A (en) 2013-11-04 2018-09-28 Dow Agrosciences Llc Optimal soybean loci
WO2015066636A2 (en) 2013-11-04 2015-05-07 Dow Agrosciences Llc Optimal maize loci
US10369201B2 (en) 2013-11-11 2019-08-06 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's disease
HRP20211706T1 (hr) 2013-11-13 2022-02-04 The Children's Medical Center Corporation Nukleazom posredovana regulacija ekspresije gena
CA2931848A1 (en) 2013-12-09 2015-06-18 Sangamo Biosciences, Inc. Methods and compositions for genome engineering
US10494434B2 (en) 2013-12-20 2019-12-03 Fred Hutchinson Cancer Research Center Tagged chimeric effector molecules and receptors thereof
WO2015116680A1 (en) 2014-01-30 2015-08-06 Two Blades Foundation Plants with enhanced resistance to phytophthora
LT3102673T (lt) 2014-02-03 2020-08-25 Sangamo Therapeutics, Inc. Beta talasemijos gydymo būdai ir kompozicijos
EP3110454B1 (en) 2014-02-24 2020-11-18 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated targeted integration
TW201538518A (zh) 2014-02-28 2015-10-16 Dow Agrosciences Llc 藉由嵌合基因調控元件所賦予之根部特異性表現
WO2015138739A2 (en) 2014-03-12 2015-09-17 Precision Biosciences, Inc. Dystrophin gene oxon deletion using engineered nucleases
AU2015231353B2 (en) 2014-03-18 2020-11-05 Sangamo Therapeutics, Inc. Methods and compositions for regulation of zinc finger protein expression
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
WO2015171603A1 (en) 2014-05-06 2015-11-12 Two Blades Foundation Methods for producing plants with enhanced resistance to oomycete pathogens
AU2015255877B2 (en) 2014-05-08 2020-03-26 Chdi Foundation, Inc. Methods and compositions for treating huntington's disease
DE102014209264B8 (de) * 2014-05-15 2017-01-12 Olympus Winter & Ibe Gmbh Hochfrequenz-Chirurgiegerät
AU2015266776A1 (en) * 2014-05-30 2016-12-08 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods of delivering treatments for latent viral infections
US10676754B2 (en) 2014-07-11 2020-06-09 E I Du Pont De Nemours And Company Compositions and methods for producing plants resistant to glyphosate herbicide
US9616090B2 (en) 2014-07-30 2017-04-11 Sangamo Biosciences, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
KR20170054445A (ko) 2014-09-16 2017-05-17 상가모 테라퓨틱스, 인코포레이티드 뉴클레아제-매개된 게놈 엔지니어링 및 조혈 줄기세포에서의 교정을 위한 방법 및 조성물
IL287561B2 (en) 2014-10-01 2024-03-01 Massachusetts Gen Hospital Methods for increasing efficiency of nuclease-induced homology-directed repair
WO2016100333A1 (en) 2014-12-15 2016-06-23 Syngenta Participations Ag Pesticidal microrna carriers and use thereof
CN107109427B (zh) 2014-12-23 2021-06-18 先正达参股股份有限公司 用于鉴定和富集包含位点特异性基因组修饰的细胞的方法和组合物
US20180002379A1 (en) 2015-01-21 2018-01-04 Sangamo Therapeutics, Inc. Methods and compositions for identification of highly specific nucleases
EP4218771A1 (en) 2015-03-27 2023-08-02 Yeda Research and Development Co. Ltd Methods of treating motor neuron diseases
US20180094243A1 (en) 2015-04-03 2018-04-05 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
AU2016250065A1 (en) 2015-04-15 2017-10-19 Dow Agrosciences Llc Plant promoter for transgene expression
JP2018511331A (ja) 2015-04-15 2018-04-26 ダウ アグロサイエンシィズ エルエルシー 導入遺伝子発現のための植物プロモーター
US11491342B2 (en) 2015-07-01 2022-11-08 Btl Medical Solutions A.S. Magnetic stimulation methods and devices for therapeutic treatments
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
US20180344817A1 (en) * 2015-05-01 2018-12-06 Precision Biosciences, Inc. Precise deletion of chromosomal sequences in vivo and treatment of nucleotide repeat expansion disorders using engineered nucleases
WO2016182917A1 (en) 2015-05-08 2016-11-17 Children's Medical Center Corporation Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
EP3294892B1 (en) 2015-05-09 2020-11-25 Two Blades Foundation Late blight resistance gene from solanum americanum and methods of use
WO2016181393A1 (en) 2015-05-11 2016-11-17 Yeda Research And Development Co. Ltd. Citrin inhibitors for the treatment of cancer
CN107849142B (zh) 2015-05-15 2022-04-26 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
WO2016187459A1 (en) 2015-05-20 2016-11-24 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
DK3310369T3 (da) 2015-06-19 2022-06-20 Prec Biosciences Inc Selvbegrænsende virale vektorer, der koder for nukleaser
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
CN108024544B (zh) 2015-07-13 2022-04-29 桑格摩生物治疗股份有限公司 用于核酸酶介导的基因组工程化的递送方法及组合物
EP3334750B1 (en) 2015-08-11 2022-10-05 Anie Philip Peptidic tgf-beta antagonists
AU2016308339A1 (en) 2015-08-18 2018-04-12 Baylor College Of Medicine Methods and compositions for altering function and structure of chromatin loops and/or domains
EP3347463B1 (en) 2015-09-08 2024-11-13 Precision Biosciences, Inc. Treatment of retinitis pigmentosa using engineered meganucleases
TW201718862A (zh) 2015-09-22 2017-06-01 Dow Agrosciences Llc 用於轉殖基因表現之植物啟動子及３’ｕｔｒ
TW201718861A (zh) 2015-09-22 2017-06-01 道禮責任有限公司 用於轉殖基因表現之植物啟動子及３’ｕｔｒ
CA3001008A1 (en) * 2015-10-05 2017-04-13 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
CN108601821B (zh) 2015-10-05 2023-09-19 精密生物科学公司 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
WO2017062790A1 (en) 2015-10-09 2017-04-13 Two Blades Foundation Cold shock protein receptors and methods of use
EP3365451B1 (en) 2015-10-22 2020-06-24 Dow Agrosciences LLC Plant promoter for transgene expression
AU2016343682A1 (en) 2015-10-30 2018-06-14 The Regents Of The University Of California Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells
WO2017079428A1 (en) 2015-11-04 2017-05-11 President And Fellows Of Harvard College Site specific germline modification
US20170121726A1 (en) 2015-11-04 2017-05-04 Dow Agrosciences Llc Plant promoter for transgene expression
CA3004497A1 (en) 2015-11-06 2017-05-11 The Jackson Laboratory Large genomic dna knock-in and uses thereof
AU2016355178B9 (en) 2015-11-19 2019-05-30 Massachusetts Institute Of Technology Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
WO2017106528A2 (en) 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the t cell receptor
WO2017106537A2 (en) 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the mhc cell receptor
WO2017112859A1 (en) 2015-12-23 2017-06-29 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
US10828318B2 (en) 2016-01-06 2020-11-10 Yeda Research And Development Co. Ltd. Compositions and methods for treating malignant, autoimmune and inflammatory diseases
EA201891614A1 (ru) 2016-01-11 2019-02-28 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Химерные белки и способы иммунотерапии
EP3402885A4 (en) 2016-01-11 2019-07-03 The Board of Trustees of the Leland Stanford Junior University CHIMERIC PROTEINS AND METHOD FOR REGULATING GENE EXPRESSION
BR112018014902A2 (pt) 2016-01-21 2018-12-18 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo plantas partenocárpicas do tipo solanácea, frutos e sementes de uma planta, produtos processados comestíveis, métodos de produção e de reprodução de uma planta,
US11261433B2 (en) 2016-01-31 2022-03-01 Hadasit Medical Research Services And Development Ltd. Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof
EP3769775A3 (en) 2016-02-02 2021-03-17 Sangamo Therapeutics, Inc. Compositions for linking dna-binding domains and cleavage domains
US20190046497A1 (en) 2016-02-14 2019-02-14 Yeda Research And Development Co., Ltd. Methods of modulating protein exocytosis and uses of same in therapy
WO2017147536A1 (en) 2016-02-24 2017-08-31 The Rockefeller University Embryonic cell-based therapeutic candidate screening systems, models for huntington's disease and uses thereof
WO2017153982A1 (en) 2016-03-06 2017-09-14 Yeda Research And Development Co. Ltd. Method for modulating myelination
EP4049665B1 (en) 2016-03-15 2025-03-12 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
ES2907837T3 (es) 2016-04-27 2022-04-26 Univ Puerto Rico 1,2,3-triazoles 1,5-disustituidos son inhibidores de las GTPasas Rac/Cdc42
EP3452583B1 (en) 2016-05-03 2021-10-27 Precision Biosciences, Inc. Engineered nucleases useful for treatment of hemophilia a
CA3021682A1 (en) 2016-05-25 2017-11-30 Cargill Incorporated Engineered nucleases to generate deletion mutants in plants
BR112018074101A2 (pt) 2016-05-26 2019-03-06 Nunhems Bv plantas produtoras de fruto sem semente
CN109689894A (zh) 2016-06-19 2019-04-26 耶路撒冷希伯来大学伊萨姆研发有限公司 在人单倍体细胞中筛选化学疗法抗性
BR112018076811A2 (pt) 2016-06-22 2019-08-27 Univ North Carolina State métodos, usos, construção ou vetor, célula, planta, material de propagação de planta, folha colhida, folha processada, produto de planta, produto de tabaco, extrato de planta e artigo de fumar
CN109844103A (zh) 2016-07-21 2019-06-04 美克斯细胞有限公司 用于修饰基因组dna的方法和组合物
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
WO2018039448A1 (en) 2016-08-24 2018-03-01 Sangamo Therapeutics, Inc. Engineered target specific nucleases
JP6866475B2 (ja) 2016-09-23 2021-04-28 フレッド ハッチンソン キャンサー リサーチ センター マイナー組織適合性（ｈ）抗原ｈａ−１に特異的なｔｃｒ及びその使用
US20190225974A1 (en) 2016-09-23 2019-07-25 BASF Agricultural Solutions Seed US LLC Targeted genome optimization in plants
WO2018064208A1 (en) 2016-09-28 2018-04-05 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
EP3518657B1 (en) 2016-10-03 2022-07-13 Corteva Agriscience LLC Plant promoter for transgene expression
WO2018067264A1 (en) 2016-10-03 2018-04-12 Dow Agrosciences Llc Plant promoter for transgene expression
EP3757120B8 (en) 2016-10-04 2022-06-15 Precision Biosciences, Inc. Co-stimulatory domains for use in genetically-modified cells
IL308894A (en) * 2016-10-14 2024-01-01 Prec Biosciences Inc Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
MX2019004487A (es) 2016-10-20 2020-02-07 Sangamo Therapeutics Inc Metodos y composiciones para el tratamiento de la enfermedad de fabry.
WO2018076335A1 (en) 2016-10-31 2018-05-03 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences Compositions and methods for enhancing abiotic stress tolerance
CA3041668A1 (en) 2016-10-31 2018-05-03 Sangamo Therapeutics, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
WO2018106782A1 (en) 2016-12-08 2018-06-14 Case Western Reserve University Methods and compositions for enhancing functional myelin production
US20200124615A1 (en) 2016-12-29 2020-04-23 Ukko Inc. Methods for identifying and de-epitoping allergenic polypeptides
EP3595708A4 (en) 2017-03-15 2020-12-16 Fred Hutchinson Cancer Research Center HIGH AFFINITY MAGE-A1 SPECIFIC TCRS AND THEIR USES
US12161694B2 (en) 2017-03-24 2024-12-10 The Broad Institute, Inc. Methods and compositions for regulating innate lymphoid cell inflammatory responses
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
EP3609890B1 (en) 2017-04-12 2024-09-11 EdiGene Biotechnology, Inc. Aryl hydrocarbon receptor antagonists and uses thereof
WO2018191520A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Respiratory and sweat gland ionocytes
EP3610266A4 (en) 2017-04-12 2021-04-21 Massachusetts Eye and Ear Infirmary TUMOR SIGNATURE FOR METASTASIS, COMPOSITIONS OF MATERIAL AND THEIR METHODS OF USE
EP3612232A1 (en) 2017-04-21 2020-02-26 The Broad Institute, Inc. Targeted delivery to beta cells
US11680254B2 (en) * 2017-04-21 2023-06-20 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the PCSK9 gene
EP3615662A1 (en) 2017-04-28 2020-03-04 Precision Biosciences, Inc. Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells
CA3061612A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
RU2019139045A (ru) 2017-05-03 2021-06-03 Сангамо Терапьютикс, Инк. Способы и композиции для модификации гена регулятора трансмембранной проводимости при кистозном фиброзе (cftr)
US11591601B2 (en) 2017-05-05 2023-02-28 The Broad Institute, Inc. Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
IL252151A0 (en) 2017-05-07 2017-07-31 Fainzilber Michael Treatment of stress disorders
AU2018266698A1 (en) 2017-05-08 2019-11-28 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
WO2018209324A2 (en) 2017-05-11 2018-11-15 The Broad Institute, Inc. Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
WO2018218038A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
US20200109408A1 (en) 2017-05-31 2020-04-09 Tropic Biosciences UK Limited Methods of selecting cells comprising genome editing events
GB201708665D0 (en) 2017-05-31 2017-07-12 Tropic Biosciences Uk Ltd Compositions and methods for increasing extractability of solids from coffee beans
GB201708662D0 (en) 2017-05-31 2017-07-12 Tropic Biosciences Uk Ltd Compositions and methods for increasing shelf-life of banana
WO2018224861A1 (en) 2017-06-07 2018-12-13 International Rice Research Institute Increasing hybrid seed production through higher outcrossing rate in cytoplasmic male sterile gramineae plants and related materials and methods
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2018237107A1 (en) 2017-06-23 2018-12-27 University Of Kentucky Research Foundation Method
EP3645054A4 (en) 2017-06-26 2021-03-31 The Broad Institute, Inc. CRISPR / CAS-ADENINE DESAMINASE COMPOSITIONS, TARGETED NUCLEIC ACID EDITING SYSTEMS AND METHODS
CN111278276B (zh) 2017-06-28 2023-05-26 美国陶氏益农公司 用于转基因表达的植物启动子
WO2019005957A1 (en) 2017-06-30 2019-01-03 Precision Biosciences, Inc. GENETICALLY MODIFIED T CELLS COMPRISING A MODIFIED INTRON IN THE ALPHA T CELL RECEPTOR GENE
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
WO2019018440A1 (en) 2017-07-17 2019-01-24 The Broad Institute, Inc. HUMAN COLON CELL ATLAS IN GOOD HEALTH AND WITH HEMORRHAGIC RECTO-COLITIS
IL253642A0 (en) 2017-07-24 2017-09-28 Seger Rony Combined treatment for cancer
JP2020529206A (ja) 2017-07-31 2020-10-08 アール・ジエイ・レイノルズ・タバコ・カンパニー 植物におけるウイルスベースの遺伝子編集のための方法及び組成物
US10430138B2 (en) * 2017-08-10 2019-10-01 Canon Kabushiki Kaisha Communication apparatus
KR20200035104A (ko) 2017-08-11 2020-04-01 프레드 헛친슨 켄서 리서치 센터 Braf 특이적 tcr 및 그의 용도
WO2019038771A1 (en) 2017-08-23 2019-02-28 Technion Research & Development Foundation Limited COMPOSITIONS AND METHODS FOR ENHANCING ALCOHOL TOLERANCE IN YEAST
EP3678690A1 (en) 2017-09-06 2020-07-15 Fred Hutchinson Cancer Research Center Methods for improving adoptive cell therapy
CA3071661A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center Strep-tag specific chimeric receptors and uses thereof
CN111315212B (zh) 2017-09-19 2022-06-14 以色列农业和农村发展部农业研究组织(范卡尼中心) 经过基因组编辑的鸟
WO2019058255A1 (en) 2017-09-19 2019-03-28 Tropic Biosciences UK Limited MODIFICATION OF THE SPECIFICITY OF VEGETABLE NON-CODANT RNA MOLECULES FOR THE SILENCING OF GENE EXPRESSION
US20200239544A1 (en) 2017-10-03 2020-07-30 Precision Biosciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
US20200255828A1 (en) 2017-10-04 2020-08-13 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
EP3697435A1 (en) 2017-10-20 2020-08-26 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
EP3700543A4 (en) 2017-10-24 2021-08-25 Elani, Dalia ISCHEMIC DISEASE TREATMENT METHODS
CN111542597A (zh) 2017-10-31 2020-08-14 美真达治疗公司 用于扩增造血干细胞和祖细胞的组合物和方法
US20190343885A1 (en) 2017-10-31 2019-11-14 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
WO2019089913A1 (en) 2017-11-01 2019-05-09 Precision Biosciences, Inc. Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
AU2018364660B2 (en) 2017-11-09 2022-05-19 Sangamo Therapeutics, Inc. Genetic modification of cytokine inducible SH2-containing protein (CISH) gene
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
US12221720B2 (en) 2017-11-13 2025-02-11 The Broad Institute, Inc. Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells
US12171783B2 (en) 2017-11-13 2024-12-24 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
IL255664A0 (en) 2017-11-14 2017-12-31 Shachar Idit Hematopoietic stem cells with enhanced properties
WO2019108619A1 (en) 2017-11-28 2019-06-06 Two Blades Foundation Methods and compositions for enhancing the disease resistance of plants
US20220267403A1 (en) 2017-12-01 2022-08-25 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
EP3707641A2 (en) 2017-12-03 2020-09-16 Seedx Technologies Inc. Systems and methods for sorting of seeds
WO2019106639A1 (en) 2017-12-03 2019-06-06 Seedx Technologies Inc. Systems and methods for sorting of seeds
WO2019106638A1 (en) 2017-12-03 2019-06-06 Seedx Technologies Inc. Systems and methods for sorting of seeds
AU2018378804B2 (en) 2017-12-06 2025-10-02 Ensoma, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
WO2019136159A1 (en) 2018-01-03 2019-07-11 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
BR112020014168A2 (pt) 2018-01-12 2020-12-08 Basf Se Proteína, ácido nucleico isolado, gene recombinante, vetor, célula hospedeira, planta, parte de planta ou semente de trigo, métodos para produzir, produto de trigo, farinha, farelo integral, amido, grânulos de amido ou farelo de trigo e métodos para identificar e/ou selecionar uma planta de trigo
EP3737226A1 (en) 2018-01-12 2020-11-18 Two Blades Foundation Stem rust resistance genes and methods of use
WO2019155465A1 (en) 2018-02-08 2019-08-15 Yeda Research And Development Co. Ltd. Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction
AU2019224051A1 (en) 2018-02-26 2020-09-03 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
CN111936617A (zh) 2018-03-16 2020-11-13 益缪索夫特公司 经遗传工程化以分泌卵泡抑素的b细胞以及使用所述b细胞来治疗卵泡抑素相关的疾病、病况、病症及增强肌肉生长和力量的方法
IT201800004253A1 (it) 2018-04-05 2019-10-05 Composizioni e metodi per il trattamento della tachicardia ventricolare polimorfa catecolaminergica dominante ereditaria.
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
WO2019200122A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene
US20210163937A1 (en) 2018-04-18 2021-06-03 B.R.A.I.N. Biotechnology Research And Information Network Ag Enrichment of genome-edited cells
PL3560330T3 (pl) 2018-04-24 2022-09-19 KWS SAAT SE & Co. KGaA Rośliny o ulepszonej strawności i haplotypach markerowych
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
US12281301B2 (en) 2018-04-27 2025-04-22 The Broad Institute, Inc. Sequencing-based proteomics
GB201807192D0 (en) 2018-05-01 2018-06-13 Tropic Biosciences Uk Ltd Compositions and methods for reducing caffeine content in coffee beans
US20210386829A1 (en) 2018-05-04 2021-12-16 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
EP3806619A1 (en) 2018-06-15 2021-04-21 Nunhems B.V. Seedless watermelon plants comprising modifications in an abc transporter gene
US11873322B2 (en) 2018-06-25 2024-01-16 Yeda Research And Development Co. Ltd. Systems and methods for increasing efficiency of genome editing
WO2020008412A1 (en) 2018-07-04 2020-01-09 Ukko Inc. Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease
CN112823011A (zh) 2018-07-09 2021-05-18 加利福尼亚大学董事会 基于t细胞的免疫疗法的基因靶标
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
GB201812603D0 (en) 2018-08-02 2018-09-19 British American Tobacco Investments Ltd Method
WO2020041380A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
BR112021003031A8 (pt) 2018-08-22 2023-05-02 Hutchinson Fred Cancer Res Imunoterapia direcionada a antígenos kras ou her2
CA3110089A1 (en) 2018-08-28 2020-03-05 Fred Hutchinson Cancer Research Center Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
EP3847159A2 (en) 2018-09-04 2021-07-14 Magenta Therapeutics, Inc. Aryl hydrocarbon receptor antagonists and methods of use
EP3853244A4 (en) 2018-09-18 2022-09-14 Sangamo Therapeutics, Inc. PROGRAMMED CELL DEATH 1 (PD1) SPECIFIC NUCLEASES
JP7344300B2 (ja) 2018-09-18 2023-09-13 ブイエヌブイ ニューコ インク． Ａｒｃベースのカプシドおよびその使用
IL322436A (en) 2018-09-21 2025-09-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
WO2020068702A1 (en) 2018-09-24 2020-04-02 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
KR20210070344A (ko) 2018-10-02 2021-06-14 상가모 테라퓨틱스, 인코포레이티드 타우 단백질의 조정을 위한 방법 및 조성물
US20220411783A1 (en) 2018-10-12 2022-12-29 The Broad Institute, Inc. Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
IL262658A (en) 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
GB201817971D0 (en) 2018-11-02 2018-12-19 British American Tobacco Investments Ltd Method
US12402610B2 (en) 2018-11-09 2025-09-02 The Broad Institute, Inc. Methods and compositions for modulating innate lymphoid cell pathogenic effectors
WO2020097530A2 (en) 2018-11-09 2020-05-14 Fred Hutchinson Cancer Research Center Immunotherapy targeting mesothelin
US12165743B2 (en) 2018-11-09 2024-12-10 The Broad Institute, Inc. Compressed sensing for screening and tissue imaging
GB201818715D0 (en) 2018-11-16 2019-01-02 British American Tobacco Investments Ltd Method
CN113544266A (zh) 2018-12-17 2021-10-22 博德研究所 Crispr相关转座酶系统和其使用方法
US20220090047A1 (en) 2018-12-21 2022-03-24 Precision Biosciences, Inc. Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
WO2020142598A2 (en) 2019-01-04 2020-07-09 Cargill, Incorporated Engineered nucleases to generate mutations in plants
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
WO2020146805A1 (en) 2019-01-11 2020-07-16 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
GB201900940D0 (en) 2019-01-23 2019-03-13 British American Tobacco Investments Ltd Method
EP3826664A4 (en) 2019-02-06 2022-10-26 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type i
WO2020172343A2 (en) 2019-02-19 2020-08-27 Massachusetts Institute Of Technology Methods for treating injuries
EP3927727A1 (en) 2019-02-20 2021-12-29 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
JP2022521010A (ja) 2019-02-21 2022-04-04 イッスム・リサーチ・デベロプメント・カムパニー・オブ・ザ・ヘブリュー・ユニバシティー・オブ・エルサレム リミテッド 薬物誘導性腎毒性を減少させるための方法
US12215382B2 (en) 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
US20220136003A1 (en) 2019-03-05 2022-05-05 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization Genome-edited birds
CA3132845A1 (en) 2019-03-11 2020-09-17 Fred Hutchinson Cancer Research Center High avidity wt1 t cell receptors and uses thereof
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2020186237A1 (en) 2019-03-13 2020-09-17 The Broad Institute, Inc. Microglial progenitors for regeneration of functional microglia in the central nervous system and therapeutics uses thereof
US20220143148A1 (en) 2019-03-14 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells
GB201903521D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd No title
GB201903520D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells
GB201903519D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
US20220152148A1 (en) 2019-03-18 2022-05-19 The Broad Institute, Inc. Modulation of type 2 immunity by targeting clec-2 signaling
CN113939586A (zh) 2019-04-02 2022-01-14 桑格摩生物治疗股份有限公司 治疗β-地中海贫血症的方法
IL316764A (en) 2019-04-03 2025-01-01 Prec Biosciences Inc Genetically modified immune cells containing shRNA-targeted microRNA (shRNAmir)
CA3136265A1 (en) 2019-04-05 2020-10-08 Precision Biosciences, Inc. Methods of preparing populations of genetically-modified immune cells
SG11202111443SA (en) 2019-04-23 2021-11-29 Sangamo Therapeutics Inc Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
WO2020227534A1 (en) 2019-05-07 2020-11-12 Precision Biosciences, Inc. Optimization of engineered meganucleases for recognition sequences
EP3969607A1 (en) 2019-05-13 2022-03-23 KWS SAAT SE & Co. KGaA Drought tolerance in corn
US20220249701A1 (en) 2019-05-14 2022-08-11 The Broad Institute, Inc. Compositions and methods for targeting multinucleated cells
GB201906768D0 (en) 2019-05-14 2019-06-26 British American Tobacco Investments Ltd Method
AR118995A1 (es) 2019-05-25 2021-11-17 Kws Saat Se & Co Kgaa Mejorador de la inducción de haploides
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
US20220243178A1 (en) 2019-05-31 2022-08-04 The Broad Institute, Inc. Methods for treating metabolic disorders by targeting adcy5
JP2022536364A (ja) 2019-06-13 2022-08-15 ザ ジェネラル ホスピタル コーポレイション 操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法
US20220251595A1 (en) 2019-06-27 2022-08-11 Two Blades Foundation Engineered atrlp23 pattern recognition receptors and methods of use
GB201909563D0 (en) 2019-07-03 2019-08-14 British American Tobacco Investments Ltd Method
GB201909562D0 (en) 2019-07-03 2019-08-14 British American Tobacco Investments Ltd Method
JP2022538647A (ja) 2019-07-04 2022-09-05 ウッコ インコーポレイテッド 脱エピトープ化されたアルファグリアジン、ならびにセリアック病およびグルテン過敏症の管理のためのその使用
US20210071193A1 (en) 2019-07-12 2021-03-11 The Regents Of The University Of California Plants with enhanced resistance to bacterial pathogens
CN114127304A (zh) 2019-07-15 2022-03-01 免疫医疗有限公司 用于蛋白二聚化的三部分型系统和使用方法
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
EP4004216A1 (en) 2019-07-25 2022-06-01 Precision BioSciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
EP4002993A4 (en) 2019-07-30 2024-01-10 Pairwise Plants Services, Inc. MORPHOGENIC REGULATORS AND METHODS OF USE
US20220298522A1 (en) 2019-07-30 2022-09-22 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby
US20220267732A1 (en) 2019-08-01 2022-08-25 Sana Biotechnology, Inc. Dux4 expressing cells and uses thereof
EP3772542A1 (en) 2019-08-07 2021-02-10 KWS SAAT SE & Co. KGaA Modifying genetic variation in crops by modulating the pachytene checkpoint protein 2
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
WO2021035054A1 (en) 2019-08-20 2021-02-25 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies
WO2021034976A1 (en) 2019-08-20 2021-02-25 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for wt-1
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP7728747B2 (ja) 2019-08-23 2025-08-25 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ２４発現細胞およびそれらの用途
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
AU2020356962A1 (en) 2019-10-02 2022-04-14 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for repressing alpha-synuclein expression
JP2022550608A (ja) 2019-10-02 2022-12-02 サンガモ セラピューティクス， インコーポレイテッド プリオン病の治療のためのジンクフィンガータンパク質転写因子
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
WO2021074367A1 (en) 2019-10-17 2021-04-22 KWS SAAT SE & Co. KGaA Enhanced disease resistance of crops by downregulation of repressor genes
IL270306A (en) 2019-10-30 2021-05-31 Yeda Res & Dev Prevention and treatment of pre-myeloid and myeloid malignancies
WO2021087305A1 (en) 2019-10-30 2021-05-06 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
WO2021087406A1 (en) 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
WO2021100034A1 (en) 2019-11-19 2021-05-27 Protalix Ltd. Removal of constructs from transformed cells
US12241830B2 (en) 2019-12-06 2025-03-04 Broad Institute, Inc. Living biosensors
EP4567109A3 (en) 2019-12-06 2025-09-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2021113543A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells
EP3835309A1 (en) 2019-12-13 2021-06-16 KWS SAAT SE & Co. KGaA Method for increasing cold or frost tolerance in a plant
IL271656A (en) 2019-12-22 2021-06-30 Yeda Res & Dev System and methods for identifying cells that have undergone genome editing
US20230026352A1 (en) 2019-12-26 2023-01-26 Figene, Llc Suppression of interleukin-17 production and inhibition of th17 cell generation by fibroblasts and products thereof
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
WO2021152587A1 (en) 2020-01-30 2021-08-05 Yeda Research And Development Co. Ltd. Treating acute liver disease with tlr-mik inhibitors
WO2021158915A1 (en) 2020-02-06 2021-08-12 Precision Biosciences, Inc. Recombinant adeno-associated virus compositions and methods for producing and using the same
CN115768446A (zh) 2020-03-25 2023-03-07 萨那生物技术股份有限公司 用于治疗神经病症和疾患的低免疫原性神经细胞
US20230263121A1 (en) 2020-03-31 2023-08-24 Elo Life Systems Modulation of endogenous mogroside pathway genes in watermelon and other cucurbits
BR112022020546A2 (pt) 2020-04-09 2022-12-20 Reynolds Tobacco Co R Método
IL297690A (en) 2020-04-27 2022-12-01 Magenta Therapeutics Inc Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
CA3177093A1 (en) 2020-05-06 2021-11-11 Cellectis S.A. Methods for targeted insertion of exogenous sequences in cellular genomes
WO2021224416A1 (en) 2020-05-06 2021-11-11 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
US20230183664A1 (en) 2020-05-11 2023-06-15 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
EP4150068A1 (en) 2020-05-12 2023-03-22 Precision BioSciences, Inc. Treatment of retinitis pigmentosa using improved engineered meganucleases
KR20230010670A (ko) 2020-05-12 2023-01-19 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 이식유전자 발현의 drg-특이적 감소를 위한 조성물
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
JP2023527446A (ja) 2020-05-29 2023-06-28 カー・ヴェー・エス ザート エス・エー ウント コー． カー・ゲー・アー・アー 植物単数体の誘導
BR112023000327A2 (pt) 2020-07-16 2023-01-31 Acuitas Therapeutics Inc Lipídeos catiônicos para o uso em nanopartículas lipídicas
WO2022020800A2 (en) 2020-07-24 2022-01-27 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
AU2021321586A1 (en) 2020-08-07 2023-03-16 Dana-Farber Cancer Institute, Inc. Therapeutic targeting of phosphate dysregulation in cancer via the XPR1:KIDINS220 protein complex
EP4192875A1 (en) 2020-08-10 2023-06-14 Precision BioSciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
EP4196568A1 (en) 2020-08-13 2023-06-21 Sana Biotechnology, Inc. Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
WO2022038536A1 (en) 2020-08-18 2022-02-24 International Rice Research Institute Methods of increasing outcrossing rates in gramineae
EP4200412A1 (en) 2020-08-21 2023-06-28 Precision BioSciences, Inc. Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene
EP4501951A3 (en) 2020-08-25 2025-04-30 Kite Pharma, Inc. T cells with improved functionality
JP2023542528A (ja) 2020-09-24 2023-10-10 フレッド ハッチンソン キャンサー センター Ｓｏｘ２抗原を標的とする免疫療法
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
CA3196599A1 (en) 2020-09-25 2022-03-31 Sangamo Therapeutics, Inc. Zinc finger fusion proteins for nucleobase editing
US20230374447A1 (en) 2020-10-05 2023-11-23 Protalix Ltd. Dicer-like knock-out plant cells
TW202222841A (zh) 2020-10-06 2022-06-16 福瑞德哈金森腫瘤研究中心 用於治療表現mage-a1之疾病的組成物及方法
US20230365995A1 (en) 2020-10-07 2023-11-16 Precision Biosciences, Inc. Lipid nanoparticle compositions
WO2022079719A1 (en) 2020-10-15 2022-04-21 Yeda Research And Development Co. Ltd. Method of treating myeloid malignancies
CR20230175A (es) 2020-10-23 2023-07-26 Elo Life Systems Inc Métodos para producir plantas de vainilla con mejor sabor y producción agronómica
US20230407333A1 (en) 2020-10-29 2023-12-21 The Trustees Of The University Of Pennsylvania Aav capsids and compositions containing same
EP4244342A1 (en) 2020-11-12 2023-09-20 Precision BioSciences, Inc. Engineered meganucleases having specificity for recognition sequences in the dystrophin gene
CA3200350A1 (en) 2020-11-26 2022-06-02 Yanay OFRAN Modified high molecular weight glutenin subunit and uses thereof
US20250032540A1 (en) 2020-12-14 2025-01-30 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
IL279559A (en) 2020-12-17 2022-07-01 Yeda Res & Dev Controlling ubiquitination of mlkl for treatment of disease
US11965022B2 (en) 2020-12-31 2024-04-23 Sana Biotechnology, Inc. Methods and compositions for modulating CAR-T activity
WO2022150616A1 (en) 2021-01-08 2022-07-14 Precision Biosciences, Inc. Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene
EP4284823A1 (en) 2021-01-28 2023-12-06 Precision BioSciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
BR112023015865A2 (pt) 2021-02-09 2023-10-31 Univ California Reguladores imunológicos envolvidos na defesa contra doenças vegetais causadas por espécies de liberibacter
EP4308694A1 (en) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
AU2022262641A1 (en) 2021-04-22 2023-11-30 Precision Biosciences, Inc. Engineered meganucleases that target human mitochondrial genomes
CA3173051A1 (en) 2021-04-22 2022-10-22 Precision Biosciences, Inc. Engineered meganucleases that target human mitochondrial genomes
WO2022226316A1 (en) 2021-04-22 2022-10-27 Precision Biosciences, Inc. Compositions and methods for generating male sterile plants
AR125467A1 (es) 2021-04-27 2023-07-19 Univ Pennsylvania Cápsides de virus adenoasociados derivados de porcinos y usos de los estos
BR112023023486A2 (pt) 2021-05-10 2024-01-30 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Composição farmacêutica, e, método de tratamento de uma doença ou condição na qual um efeito clínico benéfico é obtido pela redução na atividade de sintase de óxido nítrico neuronal
US20240218356A1 (en) 2021-05-11 2024-07-04 Two Blades Foundation Methods for preparing a library of plant disease resistance genes for functional testing for disease resistance
CN115867645A (zh) 2021-05-18 2023-03-28 赛斯尔擎生物技术（上海）有限公司 修饰细胞的方法
IL308097A (en) 2021-05-27 2023-12-01 Sana Biotechnology Inc Hypoimmunogenic cells comprising engineered hla-e or hla-g
JP2024524924A (ja) 2021-07-02 2024-07-09 トロピック バイオサイエンシーズ ユーケー リミテッド バナナ果実における褐変の遅延又は防止
AU2022309875A1 (en) 2021-07-14 2024-01-25 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
TW202317602A (zh) 2021-07-15 2023-05-01 福瑞德哈金森腫瘤中心 嵌合多肽
AR126622A1 (es) 2021-07-30 2023-10-25 Kws Saat Se & Co Kgaa Plantas con digestibilidad mejorada y haplotipos marcadores
IL310550A (en) 2021-08-04 2024-03-01 Univ Colorado Regents LAT-activating chimeric antigen receptor T cells and methods of using them
US20240358828A1 (en) 2021-08-10 2024-10-31 Gamida Cell Ltd. Engineered nk cells, methods of their production and uses thereof
MX2024001208A (es) 2021-08-11 2024-04-22 Sana Biotechnology Inc Celulas primarias geneticamente modificadas para terapia celular alogenica.
WO2023019225A2 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
JP2024534771A (ja) 2021-08-11 2024-09-26 サナ バイオテクノロジー，インコーポレイテッド 補体媒介性炎症反応を低減するための同種異系細胞療法のための遺伝子改変細胞
JP2024532772A (ja) 2021-08-11 2024-09-10 サナ バイオテクノロジー，インコーポレイテッド 低免疫原性細胞における遺伝子発現を変化させるための誘導性システム
AU2022326565A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
GB202112865D0 (en) 2021-09-09 2021-10-27 Tropic Biosciences Uk Ltd Resistance to black sigatoka disease in banana
GB202112866D0 (en) 2021-09-09 2021-10-27 Tropic Biosciences Uk Ltd Resistance to fusarium wilt in a banana
US20250002929A1 (en) 2021-09-30 2025-01-02 The Sainsbury Laboratory Plant disease resistance genes against stem rust and methods of use
WO2023064872A1 (en) 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
WO2023070003A1 (en) 2021-10-19 2023-04-27 Precision Biosciences, Inc. Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
MX2024004840A (es) 2021-10-19 2024-07-09 Prec Biosciences Inc Método de edición de genes para tratar la deficiencia de alfa-1 antitripsina (aat).
WO2023069790A1 (en) 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
US20250043269A1 (en) 2021-11-03 2025-02-06 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad Precise Genome Editing Using Retrons
WO2023081767A1 (en) 2021-11-05 2023-05-11 Precision Biosciences, Inc. Methods for immunotherapy
US11753677B2 (en) 2021-11-10 2023-09-12 Encodia, Inc. Methods for barcoding macromolecules in individual cells
US20250295807A1 (en) 2021-11-15 2025-09-25 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
US20250009800A1 (en) 2021-11-16 2025-01-09 Precision Biosciences, Inc. Methods for cancer immunotherapy
WO2023093862A1 (en) 2021-11-26 2023-06-01 Epigenic Therapeutics Inc. Method of modulating pcsk9 and uses thereof
EP4441074A2 (en) 2021-12-03 2024-10-09 The Broad Institute, Inc. Compositions and methods for efficient in vivo delivery
KR20240123832A (ko) 2021-12-16 2024-08-14 아퀴타스 테라퓨틱스 인크. 지질 나노입자 제형에 사용하기 위한 지질
WO2023111130A1 (en) 2021-12-17 2023-06-22 Tropic Biosciences UK Limited Modified agrobacteria for editing plants
CA3241193A1 (en) 2021-12-22 2023-06-29 Friedrich A. FAUSER Novel zinc finger fusion proteins for nucleobase editing
AU2022422147A1 (en) 2021-12-23 2024-07-04 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
WO2023133525A1 (en) 2022-01-07 2023-07-13 Precision Biosciences, Inc. Optimized polynucleotides for protein expression
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
MX2024009604A (es) 2022-02-03 2024-08-14 Nicoventures Trading Ltd Metodo.
WO2023148478A1 (en) 2022-02-03 2023-08-10 Nicoventures Trading Limited Method of modulating alkaloid content in tobacco plants
US20250137005A1 (en) 2022-02-04 2025-05-01 Nicoventures Trading Limited Method of modulating alkaloid content in tobacco plants
US20250302953A1 (en) 2022-02-14 2025-10-02 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
AU2023220128A1 (en) 2022-02-17 2024-08-22 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023161178A1 (en) 2022-02-22 2023-08-31 Ecole Polytechnique Federale De Lausanne (Epfl) Cgas super-enzymes for cancer immunotherapy
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
CN119562762A (zh) 2022-04-04 2025-03-04 加利福尼亚大学董事会 遗传互补组合物和方法
GB202205149D0 (en) 2022-04-07 2022-05-25 Nicoventures Trading Ltd Method
GB202205148D0 (en) 2022-04-07 2022-05-25 Nicoventures Trading Ltd Method
GB202205562D0 (en) 2022-04-14 2022-06-01 Nicoventures Trading Ltd Method
GB202205561D0 (en) 2022-04-14 2022-06-01 Nicoventures Trading Ltd Method
GB202206109D0 (en) 2022-04-27 2022-06-08 Nicoventures Trading Ltd Method
GB202206107D0 (en) 2022-04-27 2022-06-08 Nicoventures Trading Ltd Method
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
EP4522201A1 (en) 2022-05-09 2025-03-19 Synteny Therapeutics, Inc. Erythroparvovirus compositions and methods for gene therapy
US20250302994A1 (en) 2022-05-09 2025-10-02 Synteny Therapeutics, Inc. Erythroparvovirus with a modified genome for gene therapy
WO2023220040A1 (en) 2022-05-09 2023-11-16 Synteny Therapeutics, Inc. Erythroparvovirus with a modified capsid for gene therapy
WO2023225572A2 (en) 2022-05-17 2023-11-23 Nvelop Therapeutics, Inc. Compositions and methods for efficient in vivo delivery
EP4278891A1 (en) 2022-05-20 2023-11-22 KWS SAAT SE & Co. KGaA Clubroot resistance and markers in brassica
WO2024015966A2 (en) 2022-07-15 2024-01-18 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
EP4574979A1 (en) 2022-08-16 2025-06-25 Cells & Genes Biotech (Shanghai) Co., Ltd Engineered immune cell and preparation method therefor
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
AU2023329149A1 (en) 2022-08-26 2025-02-20 KWS SAAT SE & Co. KGaA Use of paired genes in hybrid breeding
WO2024056902A2 (en) 2022-09-16 2024-03-21 Christopher Shaw Compositions and methods for treating neurological diseases
WO2024079157A1 (en) 2022-10-11 2024-04-18 KWS SAAT SE & Co. KGaA Virus and insect resistance and markers in barley
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
CN120239706A (zh) 2022-11-07 2025-07-01 先正达农作物保护股份公司 改变大豆植物开花时间和/或成熟的基因及其用途
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
CN120752337A (zh) 2022-12-14 2025-10-03 伦敦王室学院 用于治疗神经疾病的组合物和方法
EP4646223A1 (en) 2023-01-05 2025-11-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
GB202300905D0 (en) 2023-01-20 2023-03-08 Nicoventures Trading Ltd Method
WO2024161022A2 (en) 2023-02-03 2024-08-08 King's College London Compositions and methods for treating neurological diseases
CN120641566A (zh) 2023-02-06 2025-09-12 蓝岩治疗有限公司 降解决定子融合蛋白及其产生方法和用途
GB202303077D0 (en) 2023-03-02 2023-04-19 Univ Oslo Brassica plants with improved seed retention
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
US12383615B2 (en) 2023-03-23 2025-08-12 Carbon Biosciences, Inc. Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
GB202305021D0 (en) 2023-04-04 2023-05-17 Tropic Biosciences Uk Ltd Methods for generating breaks in a genome
WO2024216116A1 (en) 2023-04-14 2024-10-17 Precision Biosciences, Inc. Muscle-specific expression cassettes
WO2024216118A1 (en) 2023-04-14 2024-10-17 Precision Biosciences, Inc. Muscle-specific expression cassettes
WO2024226838A2 (en) 2023-04-25 2024-10-31 The Brigham And Women's Hospital, Inc. Treatment of autoimmune diseases having a pathogenic t cell state
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
WO2024236547A1 (en) 2023-05-18 2024-11-21 Inceptor Bio, Llc Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
EP4477069A1 (en) 2023-06-16 2024-12-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Unreduced clonal gamete formation and polyploid genome design in the solanaceae
WO2024261102A1 (en) 2023-06-22 2024-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) The crl5spsb3 ubiquitin ligase targets nuclear cgas for degradation
WO2024261323A1 (en) 2023-06-23 2024-12-26 Astrazeneca Ab Molecular switches
TW202515898A (zh) 2023-06-30 2025-04-16 日商武田藥品工業股份有限公司 Ｈｔｔ抑制物及其用途
WO2025019221A1 (en) 2023-07-15 2025-01-23 Two Blades Foundation Broad-spectrum polerovirus resistance gene
WO2025049788A1 (en) 2023-08-29 2025-03-06 The Broad Institute, Inc. Optical genetic screens of intracellular and intercellular transcriptional circuits with perturb-fish
WO2025046513A1 (en) 2023-08-29 2025-03-06 Inceptor Bio, Llc Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025059215A1 (en) 2023-09-12 2025-03-20 Aadigen, Llc Methods and compositions for treating or preventing cancer
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
WO2025083169A1 (en) 2023-10-17 2025-04-24 Tenpoint Therapeutics Limited Combination of a vegf inhibitor and a complement pathway inhibitor for treating ocular disorders
WO2025101946A1 (en) 2023-11-08 2025-05-15 Precision Biosciences, Inc. Polypeptide linkers for use in engineered meganucleases
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025126153A2 (en) 2023-12-14 2025-06-19 Aviadobio Ltd. Compositions and methods for treating sod1-mediated neurological diseases
WO2025129120A2 (en) 2023-12-15 2025-06-19 Port Therapeutics, Inc. Use of thermal bioswitches for treating autoimmune diseases
WO2025129158A1 (en) 2023-12-15 2025-06-19 The Broad Institute, Inc. Engineered arc delivery vesicles and uses thereof
WO2025147573A2 (en) 2024-01-05 2025-07-10 Immusoft Corporation Glp-1 expressing modified b cells for the treatment of metabolic disease
WO2025233894A1 (en) 2024-05-09 2025-11-13 University Of Miami Engineered meganucleases that target human mitochondrial genomes
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE141646T1 (de) 1986-04-09 1996-09-15 Genzyme Corp Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US6156304A (en) 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5792640A (en) 1992-04-03 1998-08-11 The Johns Hopkins University General method to clone hybrid restriction endonucleases using lig gene
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5474896A (en) 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US6395959B1 (en) 1992-05-05 2002-05-28 Institut Pasteur Nucleotide sequence encoding the enzyme I SceI and the use thereof
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5997861A (en) 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US6265196B1 (en) 1996-05-07 2001-07-24 Johns Hopkins University Methods for inactivating target DNA and for detecting conformational change in a nucleic acid
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US7041814B1 (en) 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
EP1147209A2 (en) 1999-02-03 2001-10-24 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
CA2360878A1 (en) 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving excision of targeting dna
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
AU2001233099A1 (en) 2000-01-31 2001-08-07 Pharmacia And Upjohn Company Crystallization and structure determination of staphylococcus aureus nad synthetase
DE10131786A1 (de) 2001-07-04 2003-01-16 Sungene Gmbh & Co Kgaa Rekombinationssysteme und Verfahren zum Entfernen von Nukleinsäuresequenzen aus dem Genom eukaryotischer Organismen
DE60222914T2 (de) 2001-07-27 2008-07-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Systeme zur stellengerichteten in-vivo-mutagenese mit oligonukleotiden
EP1476547B1 (en) 2002-01-23 2006-12-06 The University of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US20060078552A1 (en) 2002-03-15 2006-04-13 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
DE10226316B4 (de) * 2002-06-10 2004-10-28 Siemens Ag Verfahren zum Einrichten eines Zusatzdientes in einem Mobilfunknetz
AU2003298574B2 (en) 2002-09-05 2008-04-24 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
AU2003290518A1 (en) 2002-09-06 2004-04-23 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
US7285699B2 (en) 2002-10-07 2007-10-23 Stowers Institute For Medical Research Ends-out gene targeting method
US20030175968A1 (en) 2002-10-30 2003-09-18 Golic Kent G. Gene targeting method
JP2006518372A (ja) 2003-01-28 2006-08-10 セレクティス 脊椎動物の体組織においてエクスビボかつイントトで相同的組換えを誘発するためのメガヌクレアーゼの使用およびその応用
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
PL1689870T3 (pl) 2003-11-18 2009-06-30 Bayer Cropscience Nv Ulepszona docelowa insercja DNA w roślinach
EP1591521A1 (en) 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
WO2006097784A1 (en) * 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
EP2327773A1 (en) * 2005-03-15 2011-06-01 Cellectis I-crel meganuclease variants with modified specificity, method of preparation and uses thereof
WO2007034262A1 (en) 2005-09-19 2007-03-29 Cellectis Heterodimeric meganucleases and use thereof
WO2007049095A1 (en) 2005-10-25 2007-05-03 Cellectis Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
WO2007093836A1 (en) 2006-02-13 2007-08-23 Cellectis Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof
WO2008010009A1 (en) 2006-07-18 2008-01-24 Cellectis Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof

Also Published As

Publication number Publication date
EP2650365A1 (en) 2013-10-16
JP6148437B2 (ja) 2017-06-14
ES2384440T3 (es) 2012-07-04
CA3055968A1 (en) 2007-04-26
US20150135345A1 (en) 2015-05-14
US8148098B2 (en) 2012-04-03
US20240228994A9 (en) 2024-07-11
US20120040405A1 (en) 2012-02-16
EP2628794A2 (en) 2013-08-21
EP2662442A1 (en) 2013-11-13
EP2484758A1 (en) 2012-08-08
EP2650366B1 (en) 2017-03-22
EP1945762B1 (en) 2013-05-01
EP2368981A2 (en) 2011-09-28
US8133697B2 (en) 2012-03-13
EP3795682A2 (en) 2021-03-24
EP2357226A1 (en) 2011-08-17
CA2626262A1 (en) 2007-04-26
AU2006304668A1 (en) 2007-04-26
US20120266266A1 (en) 2012-10-18
EP3246403B1 (en) 2020-08-26
EP2650366A2 (en) 2013-10-16
US20210284980A1 (en) 2021-09-16
EP3795682A3 (en) 2021-06-16
EP2650365B1 (en) 2016-09-14
EP2662442B1 (en) 2015-03-25
EP2628794B1 (en) 2016-05-04
US20170335299A1 (en) 2017-11-23
US20120021521A1 (en) 2012-01-26
EP2360244A1 (en) 2011-08-24
JP2024001024A (ja) 2024-01-09
US20120264189A1 (en) 2012-10-18
US20120015421A1 (en) 2012-01-19
ATE549401T1 (de) 2012-03-15
US8129134B2 (en) 2012-03-06
EP2368981A3 (en) 2011-10-12
DK1945762T3 (da) 2013-07-29
DK2650365T3 (en) 2016-12-05
DK2484758T3 (da) 2014-01-06
US20120040406A1 (en) 2012-02-16
EP2628794A3 (en) 2013-12-04
US8143015B2 (en) 2012-03-27
CA2891996A1 (en) 2007-04-26
JP6050611B2 (ja) 2016-12-21
JP5937292B2 (ja) 2016-06-22
JP2018039808A (ja) 2018-03-15
ES2829549T3 (es) 2021-06-01
JP2021054830A (ja) 2021-04-08
ES2425022T3 (es) 2013-10-10
EP2327774A2 (en) 2011-06-01
US8377674B2 (en) 2013-02-19
US20120015406A1 (en) 2012-01-19
US20120070877A1 (en) 2012-03-22
US8119381B2 (en) 2012-02-21
JP2013034473A (ja) 2013-02-21
EP2650366A3 (en) 2014-02-12
US8124369B2 (en) 2012-02-28
JP2025176009A (ja) 2025-12-03
JP2019077698A (ja) 2019-05-23
JP2022070928A (ja) 2022-05-13
EP3246403A2 (en) 2017-11-22
ES2440801T3 (es) 2014-01-30
EP2341135A3 (en) 2011-10-12
JP2009511085A (ja) 2009-03-19
EP1945762A2 (en) 2008-07-23
CA2626262C (en) 2015-09-08
US20120021520A1 (en) 2012-01-26
ES2626025T3 (es) 2017-07-21
DK2662442T3 (en) 2015-07-06
EP2360244B1 (en) 2014-12-24
WO2007047859A2 (en) 2007-04-26
DK2360244T3 (en) 2015-04-07
US20120021465A1 (en) 2012-01-26
DK2357226T3 (da) 2012-06-25
US20200109383A1 (en) 2020-04-09
US8163514B2 (en) 2012-04-24
US20240132862A1 (en) 2024-04-25
WO2007047859A3 (en) 2007-11-15
EP2484758B1 (en) 2013-10-02
US8304222B1 (en) 2012-11-06
EP2327774A3 (en) 2011-09-28
JP2012196214A (ja) 2012-10-18
DK2650366T3 (en) 2017-07-10
US20120028314A1 (en) 2012-02-02
DK3246403T3 (da) 2020-10-26
EP2341135A2 (en) 2011-07-06
US20120028315A1 (en) 2012-02-02
ES2602184T3 (es) 2017-02-20
EP3246403A3 (en) 2018-02-14
US20130227720A1 (en) 2013-08-29
AU2006304668B2 (en) 2013-03-07
US20070117128A1 (en) 2007-05-24
US8119361B2 (en) 2012-02-21
US8021867B2 (en) 2011-09-20
JP2017048179A (ja) 2017-03-09
US20120030783A1 (en) 2012-02-02
DK2628794T3 (en) 2016-08-15
EP2357226B1 (en) 2012-03-14
ES2539616T3 (es) 2015-07-02
US8143016B2 (en) 2012-03-27
ES2533370T3 (es) 2015-04-09

Similar Documents

Publication Publication Date Title
ES2582091T3 (es) Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES2575412T3 (es) Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
JP2017051190A5 (es)
BR112022008415A2 (pt) Composições e métodos para substituição do dna codificado pelo rna dos alelos
CA3166153A1 (en) Base editors, compositions, and methods for modifying the mitochondrial genome
ES2906059T3 (es) Endonucleasas de acoplamiento con enzimas de procesamiento de extremos que impulsan la interrupción génica de alta eficiencia
KR102369533B1 (ko) 뉴클레아제 프로파일링 시스템
JP2011505809A5 (es)
IL267500B2 (en) Gene editing of pcsk9 and related methods, compositions, and uses thereof
JP2016537008A (ja) Ｃａｓ９バリアントおよびその使用
AR046089A1 (es) Plantas con actividad restringida de una enzima de ramificacion de la clase 3
DE212017000061U1 (de) Zusammensetzung zum Nachweis einer einzelsträngigen Target-RNA
ES2387546T3 (es) Péptidos y moléculas relacionadas que se unen a TALL-1
JP2010517524A (ja) 偏性ヘテロ二量体メガヌクレアーゼ及びその使用
DE502005010297D1 (de) Alpha-amylase-varianten mit erhöhter lösungsmittelstabilität, verfahren zu deren herstellung sowie wasch- und reinigungsmittel mit diesen alpha-amylase-varianten
EP0624641A3 (en) Thermostable nucleic acid polymerase.
WO2023201270A3 (en) Therapeutic applications of crispr type v systems
ES2635595T3 (es) Un nuevo procedimiento para la purificación del activador tisular del plasminógeno
JP6525342B2 (ja) タグ付けされたｄｎａ断片の生成
DE60210140D1 (de) Verfahren zur herstellung von polycarbonat
WO2023147240A2 (en) Variant type v crispr/cas effector polypeptides and methods of use thereof
AR042878A1 (es) Gen de enzima formadora de peptidos
WO2023220654A3 (en) Effector protein compositions and methods of use thereof
HK1193565A (en) Coupling endonucleases with end-processing enzymes drive high efficiency gene disruption
HK1193565B (en) Coupling endonucleases with end-processing enzymes drive high efficiency gene disruption